Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.

G. Jakse,R. Hall,A. V. Bono,Wolfgang Höltl,P. Carpentier,J.P. Spaander,A. P. M. van der Meijden,Richard Sylvester

Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.

2001

G. Jakse
R. Hall
A. V. Bono
Wolfgang Höltl
P. Carpentier
J.P. Spaander
A. P. M. van der Meijden
Richard Sylvester

Objectives: This phase II study was designed to assess the response rate, side effects and long–term efficacy of BCG in the treatment of carcinoma in situ (Cis) of the urinary bladd

Keywords:

Urology
Urinary bladder
Phases of clinical research
Carcinoma in situ
Cancer
Immunotherapy
Side effect
Pathology
Urinary system
Bladder cancer
Medicine
long term results

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations